CCR8 and adult T-cell leukemia/lymphoma: In conclusion, we demonstrated that anti-CCR8 CAR T cells exhibit a stronger anticancer response than other CAR T cells against CCR8+ ATLL cells and T-ALL cells and provided a novel treatment for patients with CCR8+ T cell malignances.